Consensus nomenclature for CD8+ T cell phenotypes in cancer

Abstract : Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-01817717
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, June 18, 2018 - 12:07:19 PM
Last modification on : Thursday, February 7, 2019 - 3:26:18 PM

Links full text

Identifiers

Collections

Citation

Lionel Apetoh, Mark Smyth, Charles Drake, Pierre Abastado, Ron Apte, et al.. Consensus nomenclature for CD8+ T cell phenotypes in cancer. OncoImmunology, Taylor & Francis, 2015, 4 (4), ⟨10.1080/2162402X.2014.998538⟩. ⟨inserm-01817717⟩

Share

Metrics

Record views

54